Dr. McCloskey, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019
James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19
Dr. McCloskey, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019
0 Comments